Alnylam Pharmaceuticals (ALNY) Return on Capital Employed (2010 - 2026)
Alnylam Pharmaceuticals posted quarterly Return on Capital Employed of 20.34% for Q1 2026, up 2400.0% year-on-year from 0.81% in Q1 2025, and up 39.58% on a QoQ basis from 14.57% in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 17 years of Return on Capital Employed data on file, last reported at 20.34% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 2400.0% year-over-year to 20.34%; the trailing twelve-month figure through Mar 2026 stood at 20.34% (up 2400.0% YoY), and the FY2025 full-year result was 15.99%, up 2220.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 20.34%, up from 14.57% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 20.34% in Q1 2026 and bottomed at 31.68% in Q2 2023.
- The 5-year median for Return on Capital Employed is 6.52% (2024), against an average of 10.07%.
- The widest annual swing landed in 2024, when Return on Capital Employed surged 3526 bps; it then slumped 942 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 28.31% in 2022, then surged by 65 bps to 9.84% in 2023, then soared by 41 bps to 5.83% in 2024, then soared by 350 bps to 14.57% in 2025, then surged by 40 bps to 20.34% in 2026.
- The last three Return on Capital Employed figures came in at 20.34% (Q1 2026), 14.57% (Q4 2025), and 8.39% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -21.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.34% |
| Dec 31, 2025 | 14.57% |
| Sep 30, 2025 | 8.39% |
| Jun 30, 2025 | -5.83% |
| Mar 31, 2025 | -3.66% |
| Dec 31, 2024 | -5.83% |
| Sep 30, 2024 | -6.52% |
| Jun 30, 2024 | 3.59% |
| Mar 31, 2024 | -6.09% |
| Dec 31, 2023 | -9.84% |
| Sep 30, 2023 | -13.27% |
| Jun 30, 2023 | -31.68% |
| Mar 31, 2023 | -28.19% |
| Dec 31, 2022 | -28.31% |
| Sep 30, 2022 | -29.74% |
| Jun 30, 2022 | -26.23% |
| Mar 31, 2022 | -22.82% |
| Dec 31, 2021 | -24.76% |
| Sep 30, 2021 | -24.59% |
| Jun 30, 2021 | -26.59% |
| Mar 31, 2021 | -28.37% |
| Dec 31, 2020 | -29.89% |
| Sep 30, 2020 | -32.59% |
| Jun 30, 2020 | -37.80% |
| Mar 31, 2020 | -48.07% |
| Dec 31, 2019 | -44.40% |
| Sep 30, 2019 | -37.86% |
| Jun 30, 2019 | -44.19% |
| Mar 31, 2019 | -52.03% |
| Dec 31, 2018 | -56.35% |
| Sep 30, 2018 | -46.03% |
| Jun 30, 2018 | -35.17% |
| Mar 31, 2018 | -29.34% |
| Dec 31, 2017 | -32.64% |
| Sep 30, 2017 | -36.15% |
| Jun 30, 2017 | -38.21% |
| Mar 31, 2017 | -38.19% |
| Dec 31, 2016 | -36.72% |
| Sep 30, 2016 | -31.73% |
| Jun 30, 2016 | -29.19% |
| Mar 31, 2016 | -27.53% |
| Dec 31, 2015 | -21.94% |
| Sep 30, 2015 | -17.47% |
| Jun 30, 2015 | -14.28% |
| Mar 31, 2015 | -14.77% |
| Dec 31, 2014 | -43.19% |
| Sep 30, 2014 | -40.82% |
| Jun 30, 2014 | -37.49% |
| Mar 31, 2014 | -52.84% |
| Dec 31, 2013 | -24.45% |
| Sep 30, 2013 | -37.91% |
| Jun 30, 2013 | -33.24% |
| Mar 31, 2013 | -38.92% |
| Dec 31, 2012 | -50.45% |
| Sep 30, 2012 | -20.59% |
| Mar 31, 2012 | -20.47% |
| Dec 31, 2011 | -25.49% |
| Sep 30, 2011 | -23.16% |
| Jun 30, 2011 | -19.63% |
| Mar 31, 2011 | -17.19% |
| Dec 31, 2010 | -14.65% |
| Sep 30, 2010 | -12.15% |